- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Trial Phase
Trial Status
Paid Participation
Clear All
14 Homologous Recombination Deficiency Trials Near You
Power is an online platform that helps thousands of Homologous Recombination Deficiency patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerNiraparib Maintenance Treatment for Ovarian Cancer
Trial Details
Key Eligibility Criteria
733 Participants Needed
Olaparib for Ovarian Cancer
Trial Details
Key Eligibility Criteria
80 Participants Needed
Vudalimab + Chemotherapy/Targeted Therapy for Prostate Cancer
Trial Details
Key Eligibility Criteria
72 Participants Needed
NUV-868 + Olaparib/Enzalutamide for Cancer
Trial Details
Key Eligibility Criteria
657 Participants Needed
Niraparib + Dostarlimab for Colorectal Cancer
Trial Details
Key Eligibility Criteria
20 Participants Needed
Olaparib for Mesothelioma
Trial Details
Key Eligibility Criteria
56 Participants Needed
MOMA-313 + Olaparib for Solid Tumors
Trial Details
Key Eligibility Criteria
158 Participants Needed
Tuvusertib + Niraparib/Lartesertib for Ovarian Cancer
Trial Details
Key Eligibility Criteria
60 Participants Needed
AMXI-5001 for Advanced Cancers
Trial Details
Key Eligibility Criteria
122 Participants Needed
Pembrolizumab + Olaparib for Pancreatic Cancer
Trial Details
Key Eligibility Criteria
63 Participants Needed
EIS-12656 for Solid Tumors
Trial Details
Key Eligibility Criteria
144 Participants Needed
Chemotherapy + Rucaparib for Prostate Cancer
Trial Details
Key Eligibility Criteria
18 Participants Needed
Olaparib + ASTX727 for BRCA Mutations
Trial Details
Key Eligibility Criteria
18 Participants Needed
Combination Drug Therapy for Cancer
Trial Details
Key Eligibility Criteria
30 Participants Needed
Why Other Patients Applied
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Frequently Asked Questions
How much do Homologous Recombination Deficiency clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Homologous Recombination Deficiency clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Homologous Recombination Deficiency trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Homologous Recombination Deficiency is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Homologous Recombination Deficiency medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Homologous Recombination Deficiency clinical trials?
Most recently, we added Tuvusertib + Niraparib/Lartesertib for Ovarian Cancer, Niraparib + Dostarlimab for Colorectal Cancer and EIS-12656 for Solid Tumors to the Power online platform.